Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.
For more information, download the brochure Novozymes Facts.
Figures
|
2007
|
2006 |
| Sales |
DKK 7,438 million |
DKK 6,802 million |
| Operating profit |
DKK 1,481 million |
DKK 1,340 million |
| Net profit |
DKK 1,042 million |
DKK 911 million |
| Operating profit margin |
19.9% |
19.7% |
| Free cash flow before acquisitions as a percentage of sales |
12.9% |
15.6% |
| ROIC |
21.7% |
20.2% |
|
Water consumption, 1,000 m3 |
5,364 |
4,893 |
| Energy consumption, 1,000 GJ |
3,694 |
3,322 |
| Frequency of occupational accidents |
4.8 |
3.7 |
| Frequency of occupational diseases |
1.7 |
1.5 |
Employees
Novozymes employs some 4,500 persons half of which are Denmark-based.
Our management team (please read more here)
Steen Riisgaard
President and CEO
Per Falholt
Executive Vice President and CSO
Benny Dalgaard Loft
Executive Vice President and CFO, Investor Relations, IT and Legal Affairs
Peder Holk Nielsen
Executive Vice President for Enzymes Business
Thomas Videbæk
Executive Vice President for BioBusiness
Thomas Nagy
Executive Vice President for Stakeholder Relations
Ownership
The Novozymes A share capital is held by Novo A/S, a wholly-owned subsidiary of the Novo Nordisk Foundation. In addition, Novo A/S holds 5,826,280 B shares, which overall gives Novo A/S 25.5% of the total share capital and 70.1% of the votes.
